Dissociation between the pharmacokinetics and pharmacodynamics of once ‐daily rivaroxaban and twice‐daily apixaban: a randomized crossover study

ConclusionsDespite similar exposure to both drugs, rivaroxaban 20 mg once daily was associated with greater and more sustained inhibition of thrombin generation than apixaban 5 mg twice daily. Sensitive prothrombin time and activated partial thromboplastin time assays can be used to estimate the anticoagulant effects of rivaroxaban.This article is protected by copyright. All rights reserved.

Source: Journal of Thrombosis and Haemostasis - August 1, 2017 Category: Hematology Authors: Reinhold Kreutz, Pontus B. Persson, Dagmar Kubitza, Kirstin Thelen, Stefan Heitmeier, Stephan Schwers, Michael Becka, Melanie Hemmrich Tags: Original Article ‐ Coagulation Source Type: research